About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

NCT01799473·52 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

United Therapeutics

Age

Any age

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Are newly prescribed Tyvaso for the treatment of PAH and plan to initiate therapy
Are willing and able to be contacted by the patient call center.

You may not be if

Have previously received Tyvaso.
Are currently enrolled in an interventional (non-FDA approved) PH clinical trial.

The record

StatusCompleted

PhaseNo phase

Taking part98

StartedJan 2013

UpdatedMar 24, 2015

Conditions

Pulmonary Arterial Hypertension

Where52

The Regents of the University of California
La Jolla, California, United States
UCLA Medical Center
Los Angeles, California, United States
Southern California Permanente
Pasadena, California, United States

Clareo Health | Tyvaso Dosing and Titration Evaluation: TyTRATE Registry